TriSalus Life Sciences, Inc. will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2026. The oncology company, which integrates novel delivery technology with standard-of-care therapies, will issue a press release detailing the results prior to the call.

Parties interested in participating by phone must register using an online form to receive dial-in details and a PIN. The event will also be webcast live on the investor relations section of TriSalus’ website, with a replay available following the event.

Conference Call Details

About TriSalus Life Sciences

TriSalus Life Sciences is a medical technology company focused on transforming outcomes for patients with solid tumors. Its platform includes devices utilizing proprietary Pressure-Enabled Drug Delivery (PEDD) technology and a clinical-stage investigational immunotherapy called nelitolimod. The company’s FDA-cleared devices include the TriNav Infusion System and the Pancreatic Retrograde Venous Infusion System. TriSalus is currently completing data for several phase 1 clinical trials and plans to explore partnership opportunities for development.

Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. concerning potential securities fraud or other unlawful business practices by the company and its officers. The investigation follows a significant drop in the company's stock price after it announced a reduction in its full-year revenue guidance and disclosed delays in regulatory approvals.

On May 12, 2026, TriSalus reported financial results for the first quarter of 2026. The company recorded revenue of $8.90 million, representing a decline of 2.92% year over year. Following this report, TriSalus announced it was cutting its full-year revenue guidance to a range of $54 million to $57 million. This new guidance represents a reduction of $5.5 million at the midpoint compared to prior guidance.

Factors Behind Guidance Revision

During an accompanying earnings call, TriSalus’s management attributed the guidance revision to lower Q1 revenues from commercial expansion and delayed FDA clearance timing for TriNav Advance. Management disclosed that FDA clearance for TriNav Advance is now running approximately 5 months past the 30-day MDUFA review goal.

Market Reaction

The announcement negatively impacted the company's stock performance. On May 13, 2026, TriSalus’s stock price fell $1.89 per share, or 41.56%, to close at $2.67 per share.